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Objectives. This study was done to provide informatiw on the 
potential bene61 of implantaMe cwdtowter-dcfibriUator therapy 
&her&h therapy impr& survival. 
Background. Implantation of automatic csrdiovertw 
LOrtUslors is reparted to abort sudden cmdtsc death due to 
malignant achyarrhythmias. 
total arrhythmis.rel.ated eath and t&at CX&C death wwe 
omtpared with the ocowrence of Iat venbicular texhywhyth- 
miss L’QAO beat&tht), assutuiag that mast of that urbythmiPa 
would have been i&al without treatment by the implantable 
c;lrdioverter.defib~i%tor. 
Implantable cardiovcrter-defibrillators have been widely 
used for therapy of ventricular tachycardias and prevention 
of recurrence of sudden cardiac death. A remarkably low 
incidence of recurrent sudden cardiac death has been re- 
ported by nunwous investigators (I-4). implantation of au 
automatic defibrillator is now considered dinical practice for 
selected patients C-8) despite the lack of controlled trials. 
However, some investigators (9-11) have recently argued 
that implantable cardiovener-de8brillator therapy prevents 
sudden cardiac death but not total cardiac death or arrhyth- 
mia-related death (defined as surgical mortality plus sudden 
cardiac death plus death within 24 h after an atrhythmic 
event despite initinl term&don of the tachyarrhyrhmia by 
the device). This study ws performed lo analyze the poten- 
tial benefit of implantation of an automatic defibrillator in 
patients with refractory ventricular whyarrhythmias or 
aborted sudden death. 
RemUs. The surglcd mortality rate was 2.7% in ail IO7 
patients and 1% in the 99 pa&n& rho qua&d for endaardkd 
leads. lturiug a falhwup period of 12 f 8 months, actwial 
survival~~~OIevCII$at6mDllthSllSwell~atI2~18 
months lyp~ 100% for sudden death, 91% for totnl arrhylbmii 
related death and 95% for total cardtr death. In oontrast, after 
6, 12 and 18 montks, the nte of survivnl fwe of E& vmtric&r 
tachycmdia was cmly 83%. 74% and 69%. rwp&iv&, aml the 
rate of survival free al any veatrkulrr tacbyarrbflmia WPI only 
59%,49% and 40%, respeetlvely. 
(J Am Cdl CwdioI 1993;21:1638-41) 
MethOdS 
Study patknts (Tat& 1). We studied 107 consecutive 
patients who underwent implantation of a third-generation 
automatic defibrillator cornbitted with endowdial defibrilla- 
tion leads for refractory malignant tachyarrhythmias or 
aborted sudden death during the period between October 
1989 and March 1992. Written informed consent war ob- 
tained from all patients. There were 86 men and 21 women 
with a mean age of 57 f 13 years. Coronary artery disease 
was present in 68 patients, dilated cardiomyopathy in 21, 
hypertruphic cardiomyopathy in 2, valvular hearc disease in 
3. arrhvthmoaenic rieht ventricular disease in 9. atrial seutal 
defect -in 2,‘QT syndrome in I patient, an6 a complex 
congenital defect in I. Mean left ventricular cjoction fraction 
was 40 ? 15%; 31 uatiems had an eiection fraction ~30%. 
Thirty-one patient; were admitted ior primary ventricular 
fibrillation. 53 had experienced sustained ventricular fachy- 
cardia, I9 had experienced both ventricular tachycardia and 
fibrillation and 4 with previws myocardial infarction had 
syncope and inducible ventricular tachycardia. Fifty-eight 
patients had been resuscitated at least unce before imln- 
tation of the device. Sustained ventricular taehycardiawas 
defined as a veotricular tachycardia lasting X0 s or requir- 
ing premature temdnatian because of hemudynamic cum- 
promise. 
At the time of admission to the hospital and at implanta- 
Tab 1. Patient Charxmistics 
.-- .____ 
tion, no patient was in New York Heart Association func- 
tional class IV. 
Implos(siion technique. A nonthoracotomy approach 
was intended in all padents. Thr electrode lead system used 
included a wansvenous lead-subcutaneous patch system 
(Cardiac Pacemakers Inc. [CPII Endotak or Medtmnic 
Transvene) in 84 patients and a transvenoos lead system 
(Endotak) in 15 patients. In eight patients. epicardial patches 
were utilized. Devices used included the CPI Ventak PBX in 
32 patients, the CPI Ventak P2 in 19 and the Medtronic 
c&liovet’tcr-defibrillator PCD in 56. All devices used are 
capable of storing intracardiac electrogmms (Ventak P2) or 
RR intervals Wentak PRX, PCD) before and after delivering 
therapy, thus allowing correct classification of trealed tachy_ 
car&as. 
The PRX and Vent&. P2 were programmed to perform a 
reconfirmation of the detected h&t rate immedi&ely after 
capacitor charnina. In case of failore of reconfirmation. the 
sh&k delive~ishivened and lhc charge is dumpd to an 
internal load. 
Time to first shock delivery included 18 cycles of rachy- 
cardia for detection (in Ventak P2 2.5 s instead of u fixed 
aumber of cycles were required). about 8 s for capacitor 
charging and 4 cycles for reconlinnalion of the tachycardia 
in the PRX and Ventak P2. 
~tlarrbylhndc drug lhwapy. Three (2.9%) of the I04 
patients who survived were discharged on class 1 antiar- 
rhyihmic drug therapy and 13 (12.5%) of the 104 received 
class III anfiarrhythmic drugs. even though these drugs were 
demonstrated to be ineffective during electmphysiologic 
testing before implantation of the device. In these I6 pa- 
tients, the indications for such therapy included suppression 
of frequent tachycardias in 8 patients. loweriog of the 
defibrillation dweshold in 2 and slowing the rate of Ihe 
tachycardia lo make overdrive pacing possible in 6. In 
addition, 46 (44.2%) of the 104 p&ems were treated with 
drgi!aiis io prolong atr’oventrictdar (AV) conduction w 
beta-adrenergic blocking agents 10 prolong AV conduction 
or slow sinus rhythm. 
Follow-up. All patients were followed up in the pace- 
maker clinic ofourinstitutionat intervals of2months. Study 
end paints were the following: surgical mortality (defined as 
death of any cause within 30 days after o~ratkm). sudden 
death (defined as either death within I h after the onset of 
initial symptoms or unwitnessed death), arrhythmia-related 
nonsudden death (defined as death within 24 h of a venttic- 
ular Whyarrhythmia despite initial termmation of the tachy- 
cardia by the device), nonarrhythmic cardiac death and 
noncardiac death. Total arrhythmia-related eath was de. 
fined as aur81cal mortality plus sudden death plus arrhyth- 
mia-related nonsudden death. 
All device discharges were classified by two indepeodent 
cardiologists es inappropriate (that is. discharge of the 
device for ahial fibrillation or sinus tachycardia) or as 
appropriale according to recorded electmgtams. RR interval 
memory before tirst treatment by the dewce and tachycar- 
dia-related symptoms. Preliminary results from our labora- 
tory 112) suggest that classilication of tachyarrhylhmiss 
according 10 cycle length memory utilizing mean cycle 
length. stability of the tachycardia and sudden onset may be 
useful. Recorded no&al events included ventricular tachy- 
arrhythmias (of either rate) and fast ventricular tachyar- 
rbytbmias arbitrarily defined as ventricular tachyarrbyth- 
mias >246 beatrlmin. Because of reported data (13) on 
surgery-related exacerbation of ventricular lachyarrhyth- 
miss. episodes occurring within 1 days after operation were 
excluded from further analysis. Benefit of implantation of an 
automatic defibtill;rtor was estimated by the difference be- 
tween total arrhythmia-related eath and rate of fast ventic- 
ular :ac!!yerrh$nias. assuming that most fast ventricular 
tachyarrhythmiarwuld have been fatal without termination 
by the implanted defibrillator. 
Stati.&al meuods. Staadard deviation (mean + SC) was 
used as the index of dispersion of the variables measured. 
The log-rank test was used to compare survival rates. A 
two-tailed probability value < 0.05 was considered signifi- 
cant. Data were analyzed on an intention to treat basis. 
ReSUltS 
Operative results. A ~tal of 107 patients were screened 
for implantdtion of a third-generation implantable cardio- 
veneidelibrillator. During implantation, the defibrillation 
threshold (defined as the miobnal enemv required for temd- 
nation of induced ventricular Abrillation) &determined by 
stepwise reduction of defibrillation energy. In 99 patients 
192.5%). a sufficiently low defibrillation threshold could be 
achieved, thus allowing implantation of the device. For 
those patients who qualified for implantation of tramvenous- 
subcutaneous leads, the mean dcfibrillarion threshold was 
14.6 f; 5.9 J. Lea< confomrations utilized included h-am- 
venous-subcutaneoia leads (right ventricular apex, cathode; 
superior caval vein, anode; subcutaneous natch, anode) in 35 
patients; trausveuou~ leads (right ventricular apex, cathode; 
sunerior caval vein, anode) in 15 patients with the Endotak 
sy&m; and transvenous-subcutaneous [(right ventricutar 
apex, cathode; superior caval vein, anode I; subcutaneous 
patch, anode 2) in 44 patients; (superiorcaval vein, cathode: 
right ventricular apex. anode I; subcutaneous patch, anode 
2) in I patient; (right ventricular apex, cathode: subWaneons 
patch, anode) in 2 patients; (right ventricular apex, cathode; 
coronary sinus, anode 1; subcutaneous patch, anode 2) in 2 
patients] in 49 patients with the Transvene system. AU but two 
of the Medtronic PCD devices combined with endocardial 
leads were programmed to srqu.utiut shccks; these two de- 
vices were programmed to singhe shocks. AU Ventak F2 
devices were progratnmed to deliver biphasic shocks. 
Eight (7.5%) of the 107 patients with a detibrillation 
threshold >20 J did not qualify for implantation of endocar- 
dial lead systems. Instead, epicardial defibrillation leads 
were implanted using the subxiphoid approach in six patients 
and by stemotomy in two. 
Pustoprative course. Padents with an endocardia: ‘vd 
sysrem. One patient died in the hospital within 30days after 
operation, restthing in a surgical mortality rate of 1% for the 
patients who qualified for implantation of transvenous leads. 
This patient had been operated on for atrial septal Q:fect 7 
years before device implantation and had to be resuscitated 
twice for ventricular tachycardia. She had a bleeding disor- 
der because of advanced~liver disease. This patient devel- 
oned a hemothorax after nerforation of the subclavirm vein 
during insertion of the hansvenou~ lead. The lead was 
inserted in addition to two pacemakerwires that could not he 
extracted. She eventually died 5 days after operation as a 
result of this bleeding and multiorgan failure. She had no 
arrhythmic events after imnlantation of the defibrillator. 
patients with an epicor& leadsysrem. One patient died 
of adult respiratory distress syndrome 7 days after opera- 
tion. This patient had had an inferformyocardial infarction 3 
months before operation. Because of recurrent ventricular 
fibrillation despite treatment with amiodarone, the decision 
to implant an implantable cardioverter-defibrillator was 
made. Three days postoperatively, he developed rapid pro- 
gressive dyspnea without signs of infection and had to be 
treated with mechanical ventilation. He died of multiorgan 
failure 4 days later. Another patient with dilated cardiomy- 
opathy and end-stage renal failure who had been admitted 
because of aborted sudden cardiac death died of pulmonary 
embolism I2 days postoperatively. At autopsy, diagnosis of 
pulmonary embolism and thrombosis of both femoral veins, 
both iliac veins and both jugular veins was conlimted. 
Long+xm follow-up (Table 2). During the followvp pe- 
riod of 12 + 8 months, there were only two deaths. A 63.year 
old patient with hypertrophic cardiorrryopathy and coronary 
artery disease died of acute myocardiat infarction with 
myocardialfailure 5 weeks after device implantation. He had 
recurrent polymorphic tachycardia before implantation of 
the cardioverter-defibrillator. Because hnplantation of an 
endocardial ead system had not been successful, the subxi- 
phoid approach was used for implantation of epicardial 
leads. Eleven days postoperatively. he experienced poly- 
morphic ventricular tachycardia that was successfully temti- 
nated by the device. He had a myocardiat infarction 29 days 
postoperarively and eventually died of progressive heart 
failure. No tachyarrhythmias were noted before his death. A 
70.year old patient died 4.3 months after device imptautation 
because of progressive heart failure. Ejection fraction was 
38% at the time of implantation and he was in functional 
class HI. He experienced a first fast ventricular tachycardia 
2 months after operalion and 13 episodes during the follow- 
ing month. He did well until 3 months after operation when 
he was admitted for progressive heart failure to another 
hospital. His hemodynamic status gradually deteriorated aad 
he died 3 weeks after admission. No ventricular tachyar- 
rhythmias were observed before his death 
During the follow-up period. 51 patients h-d a total of 
1,162 ventricular tachycardias (median 8, rarga I to 261 
ventricular tachycardiaslpatienl) lhal were treated by the 
devices. Twenty-six of these 51 patients had fast ventricular 
tachycardias. Notre of the 51 died suddenly or within 24 h 
after tachycardia was tertoinated by the implanted delibril- 
lator (Fig. I). Figure 2 shows the difference between 1) total 
arrhythmibrelated death, and 2) fast ventricuhu tachyar- 
rhythmia presumed to be fatal without lertnination by the 
device. This difference in survival rate was 14%, 23% and 
28% at 6,12 and 18 months, respectively, indicating abenefit 
for patients with implantation of an automatic defibrillator. 
Subgroup analysis was done for patients with an ejection 
fraction ~48% versus >48% and for patients with versus 
without coronary artery disease (Fig. 3). Results are sum- 
marized in Table 3. For patients with an ejection fraction 
548%. the ditference between total arrhythmibrelated death 
and fast ventricular tachycardii was I I%, 20% aad 26% at 6, 
12 and 18 months, respectively. For patients with an ejection 
fraction >40%, the difference was IS%, 27% and 32% 
respectively. For patients with coronary artery disease, the 
ditference between total arrhythmia-related death aad fast 
ventricular tachycardia was 14% 25% and 25% at 6. I2 and 
18 months, respectively. For patients without coronary 
artery disease, the difference was 17% 21% and 36%. 
respectively, at the three time intervals. 
Figure 1. Survival rates for freedom from sudden dearh, tolal 
cardiacdcath. total arrhythmia-related death (sxgical monathy plus 
sudden death plus nonsudden arrhythmia-related death). fast ven- 
tricular tachyarrhythmias (>240 beatsimird ad all ventricular tach- 
yarrhythmiis. VTNF = venbicolar tachycardi&entricula fib&.- 
lion. 
In 51 patients with a PRX or Ventak P2 system. the rate 
of spontaneous tenoination of tachycordia during the period 
required for charging the capacitors could be analyzed. The 
diversionot acharge to the internal load occurred in7 (1.6%) 
of all 436 treated tachycardias aad in I (3.8%) of 26 fast 
ventricular tachycardias. In the latter case three more epi- 
sodes of fast ventriculat tachycardia occurred that were 
successfully terminated by the device. This patient also 
expuienced syncope in one of these episodes. 
Discussion 
The results of this study suggest that the outcome of 
patients with a relatively good ejection fraction treated with 
Figure 2. Estimation of the beneMel etTects of implant&n of 
automatic defibrillators by the difference between total arrhythmia- 
related death aad fast (presumably life-threatening) ventricular 
tachyarrhythmias. VTlvP = ventricular tachvcardi;iventricular 5. 
bdllation. 
a third-generation implantable defibrillator in combination 
with bansvenous defibrillation leads is excellent. 
Surgtsal mortaltty. The surgical monrtlity rate in our 
study was markedly lower than that reported in many other 
studies ofepicardial patch electrodes. In a study reponed by 
Winkle and Thomas (14). 31 (4.6%) of 669 padents without 
concomitant surgery died within 30 days a&r implantation 
of a defibrillator with epicardial catch electrodes. Kim et al. 
(IO) reported a 4% s&ical m&dity rate in 378 patients 
treated with epicardial patches. Saksena et al. (15) reponed 
a 5.5% perioperadve mortality rate in 203 patients treated 
with an implantable defibnllator and epicardial patch elec- 
trodes. Cohen et al. (16) reported a p&operative motiity 
rate of 8% in II I patients treated with an implantable 
cardiovsrter-defibriilator in combination with epicardial 
patch electrodes. Compared with these results, the surgical 
monality rate in our sidy is low. providing an argoreeat for 
using the transvenous (or tmnsvenous-subcutaneous) ap. 
proxh as first choice for implantation of defibrillation elec- 
trodes. 
Sudden death. There was no sudden death in our study 
group. This result is somewhat better but not significantly 
ditTerent from that previously reported. Saksena et al. (15) 
reported tu’o sudden deaths in 2W palienrs with epicardial 
electrodes during a mean follow-up period of I2 months. 
Kim et al. (9) reported six sudden deaths, including two that 
occurred widen the 1st 12 months, in 68 patients. Winkle et 
al. (4) reported an annual sudden death rate of 1.5%. Our 
results demonstrate that tnnsvenous electrodes are at least 
as effective as epicardial patches for the prevention of 
sudden cardiac death. 
Tolal arrhythmk de&h. No arrhythmic death was ob 
served other than that classified as sui-gical motlalily. Ttis 
result is similar to other reports (15) but differs from those 
reported by Kim et al. (17). whose 68 patients had an 
acomrial survival rate free from arrhythmic death of 97% 
amona those with an eiection fraction >3G% at 12 manths 
and a~survival rate of-82% among those with an ejection 
fraction ~30% at I2 months. In our study, none of 30 
patients with such pwr left ventricular function died. Non- 
sudden arrhythmia-related death seems to be a rare finding 
because it was not ODserwd in our group despite multiple 
episodes of ventrictdar tachyarrhythmias treated by the 
devices. 
Ien& from defibriyptor implmtt&t~. There is no con- 
senstts about the !xneftt fmm implantation of automatic 
defibrillators (6). Controlled trials are still lacking (IS). and 
because implantation of defibtillators has become estab- 
lished clinical practice, such trials will bc dillicult to per- 
form. Earlier reports have used discharges fmm implantable 
detibrillators to determine their benefit, thus using treated 
patients as their own control group. Because venlricular 
tachycardias are not necessarily fatal in many patients and 
many implant&e cardioverter-defibrillator discharges are 
not delivered appropriately this appmach overeslimates the 
benefit of automatic defibrillator% As a slightly different 
low EF 
Figure 3. A to D, Actwi~J survival rates for freedom from anhyth- 
mia.related death and fast ventricular tachyanhythmias (2240 
katslmin). A, Patients with coronary artery discnse (CAD). B, 
Patients with diseases other than coronary artery disease. C, Pa- 
tients with an ejection fraction (EF) 540%. D. Palients with an 
ejection fraction 240%. VTNF = ventricular tachycardial 
ventricular fibrillation. 
approach, only discharges that are combined with syncope 
or near syncope have been used for calculation ofthe benefit 
of implantation of defibrillators. However, as automatic 
defibrillators may treat dangerous ventricular tachycardiar 
even before symptoms occur, this approach leads to an 
underestimation of the benefit of treatment with implantable 
defibrillators. This limitation can be minimized by third 
generation defibrillators that are able to store cycle lengths 
or intmcardiac ekctrograms of treated arrhythmias. thus 
allowing classification if treated tachycardias. 
Because the maioritv of fast tachvcardias are life- 
threatening, the diff&~e between su&al fmm arhylh- 
m&elated death and actwifd survival from fast ventricular 
tachycwdia results in a valuable estimation of the be&it of 
implantation of automatic defibdlators. IO our study, this 
difference suggests a substantial benefit from implantable 
cardioverter-detibrilktor implantation for many patients. 
Thebenefit seemsnot tobe d%inirhedforpatients with poor 
left ventricular function, as has been suggested by Kim et al. 
(lOJ7). 
Antkrrbytbmk drug chcrspy. It has been common clini- 
cal practice to prescribe antiarrhythmk drug therapy for 
most patients after implantation of an automatic defibrillator 
to reduce the frequency of ventricular tachyarrhvthmias 
(13.19). In these pahents. either untested d&or d&s that 
have failed elcctrophysiologic testing were used. In contrast 
to these studies, only a minority of our patients were 
discharged on treatment with class I or class III antiarrhvth- 
mic dru&. Most antiarrhythmic drugs have potential tox;city 
and prowrhythmic effects (20). In addition, Kou et al. (21) 
could not demonstrate a reduction in the recurrence of 
ventricular tachyarrhythmias by antiarrhythmic drug ther- 
apy in 14 patients who received an implantable cardioverter- 
defibrillator after a single episode of veotricular tachyar- 
rhythmia. In their study, a significant increase in the 
incidence of syncope at the time of implantable cardiovener- 
delibriIIator discharge was observed. Thus, there did not 
appear to be a strong rationale for using anriarrhythmic 
drugs after implantation of the device. Because only a 
minority of our patients c’cc trested with c!ass I or ciass III 
antiarrhythmic drugs. a significant exacerbation of ventricu- 
lar tachyarrhythmias by the drug treatment seems unlikely. 
Limitations of the present study. Several aspects of the 
present study require comment. In this analysis of the 
impact of implantable cardioverter-defibriIlaors on sudden 
cardiac death, arrhythmia-related death and cardiac death, 
study patients served es their own controls. In contrast to 
earlier studies, only patients receiving a third-generation 
implantable cardioverter-defibrillator capable of storing 
tachycardia cycle lengths before device therapy were in- 
cluded. 
Because shxver tachycardias might be hemodynamically 
tolerated for a certain time, only very fast ventricular 
tachycardiis (>240 beats/ruin) were included in the analysis 
of projected survival without the implantable defibrillator. 
However. an insignificant overestimation of the benefit 
imposed by implantable cardiovener-defibrillators cannot be 
excluded because a minority of the patients might have 
survived a fast ventricular tachycardia long enough to obtain 
medical attention. 
Another souxe for overestimation of the rate of appro- 
priate implantable cardioverter-defibrillator therapy is the 
triggering of discharges by self-terminating tachycardias. 
However, patients experiencing the occurrence of self- 
terminating tachycardirts before implantation of the device 
were treated with an&rhythmic drugs to control for this 
occurrence. Purthennore. evidence exists that fast ventric- 
ular tachycardias howed no tendency to he self-teninating. 
In 51 patients with a PRX or Vent& P2, only seven episodes 
of ventrictdartuchycardia nd one episode offart ventricular 
tachycurdia spontaneously terminated during the period 
required for charging the device. Although not very likely, it 
cannot be excluded that some of the episodes of fast vcn- 
tricuku tachycxdia might have been self-terminating after 
the period of the device discharge. 
The occurrence of supraventricular tachycwdias with a 
rate >24Obeats/min is highly unlikely because in all patients 
accessory pathways were excluded and Fast AV conduction 
was always treated with an&rhythmic drugs. 
In the majority of patients, tachycardiar were classiiied 
by utilizing stored RR intervals before the first impkmteble 
cardioverter-defibrillator therapy and lachycardia-associ- 
ated rymptoms. Although this classification does not provide 
perfect accuracy, Block et al. (12) demonstrated that classi- 
fication of tachycardias using RR memory allows correcl 
classification of treated tachycardias in the majority of 
episodes. For tacbycardias with a rate >240 beatslmin. 
classification between ventricular tachycardiaand rupraven- 
tricular tacbycardia was only a minor problem because 
accessory pathways were nt!cd out in al1 patients during the 
baseline electrophysidogic study. In addition, a sigoilicaut 
number of the patients were treated with digitalis or beta. 
blockers to prolong AV conduction. Double-sensing of 
broad QRS complexes or oversensing of T waves during 
tachycardia that could imitate fast ventricular tachycardia 
were not observed in any of the patKnts duringtestingofihe 
devices in the electmphysiologic laboratory. One patient 
with a Ventak PRX (model 1700) had a defect isolation of an 
adapter that connected the device and the endocardial iead. 
He had internGttent oversensing of myoporentials that led to 
inappropriate discharges by the device. This defect could 
easily be differentiated fmm fast ventricular tachycardia 
because the cycle lengths preceding the shock were emu- 
pletely irregularcthat is. ranging from <150ms to >Wl msl. 
The patients in our study were not homogeneous. reflect- 
ing the use of the implantable cardioverter-defibrillator nat 
only for end-stage heart disease but as a therapeutic z,P- 
preach of choice for putients with malignact Ischyarrhyth- 
miss either not inducible at electmphysiologic study or 
refractory to medical treatment. The benefit of implantable 
cardioverter-defibrillator theraw could be demonstrated for 
patients either with u low or ahigh ejection fraction and for 
patients with or without coronary artery disease. 
The ejection fmftion in our patients was relatively high 
compared with those from earlier reports. In comrast 10 
other reported studies we implanted au implaWbIe cardio- 
vetter-defibrillator in a substantial number of patients with 
arrhythmogenic right ventricular disease. These patients had 
a good left ventricular but a poor right ventricular ejection 
fraction. Moreover, a higher ejection fraction that was also 
reported in other studies with third-pneratiw implantable 
cardioverter-defibribators retlects thewe of mode& delibril- 
laws not only in patients with end&age disease but as 
established treatment of ventricular tacharrhythmias refrac- 
tory to medical treatment. In the study of Bardy et al. (22). 
the mean ejection fraction was 39% for all patients treated 
with a Medtronic PCD and 40% for patients with endocardial 
leads. In the study reported by Framer et al. (23). the mean 
ejection fraction in al~patientstreated with a Medtronic PCD 
was 36%. 
The relative short follow-up period in our study is com- 
parable to that of other studies with second- and third- 
generation implantable cardioverter-de6brillators (15,22,23). 
Although a longer follow-up may be desirable, a significant 
benefit by implantable cardioverter-defibrillator therapy 
could he demonstrated even for thn short period. .4 WI- 
dcncy to Icss benciit wih a longer fc,liow-up uas not 
ubrervcd. 
Conctucions. The resuhs of our study suggest that in 
patientc with aborted cudden cardmc death or refractory 
mahgnant wntricular tachyarrhythmias. lmpiantable dc- 
fibrillatori combined with tranwznous or tranwenow 
subcutancow leads arc very cffcctive not only in preventing 
sudden cardiac 31-z;:. ‘ki also in reducing arrby!hC-related 
death and (most tmponantl torat cardiac death. They seem to 
be superior to defibrillators with epicardial defibrillation 
palchea because of a lower surgical motility rate. The 
beneficial effect of defibrillator implantation applies not only 
to patients with good left ventricular function but also to 
those with ilrpaned left venrricularfunction. Furtbcr s;iidies 
are needed to dctcrmin: whether epicardial patches may 
lead to hemodynamic deterioration and may thus be the 
cause for the apparently (though not statistically provrd) 
higher rate of nonsudden cardiac death ,>hserved in other 
studies. Another reason for the low incidence of nonsudden 
arrhythmia-related death in our study mxght 5. the low rate 
of patients treated with antiarrhythmic drw that have 
negative inotropic side effects. Further studies ac needed to 
determine the role of antia-hythmic agents in patients with 
an implantable cardiovener-defibrillator. Implanlatton of an 
automatic defibrillator in combination with trans~enou~ lead 
systems is probably lifesaving for patients wth refractory 
ventricular tachyarrhythmia or aborted sudden cardiac 
death. 
18 Bigger 1’f F”t”s studies with the impiantablz cardwrrtrr drfibnllatar 
PACE 199,:,4:881-Y. 
